Adaptable : to the physician’s and the patient’s therapeutic goals.
Repeatable : if needed at any time during follow-up.
Not a therapeutic impasse : alternative options still open post Ablatherm.
Ergonomic control panel :
Powerful software combines the visualization
and the control of the entire treatment process : The software enables a constant monitoring of the treatment process from the definition of treatment area by
ultrasound and the three-dimensional planning of the treatment to the firing phase with a real time monitoring of the transducer position.
Optimization of performance :
The Ablapak : A single use medical disposable. It contains the
Ablasonic liquid that enables the optimal transmission
of accoustic energy to the tissue.
The circulating liquid is cooled and thus ensures the
thermic protection of the rectum.
Localized prostate cancer : • First choice therapy
• Salvage therapy for local recurrence after external
radiotherapy or radical surgery.
The bi-plan ultrasound imaging probe enables a precise three-dimensional visualization of the treatment area.
The combination of the essential imaging quality with the strength of the treatment planning software makes the Ablatherm safe and efficient.
For a safe and precise positioning :
Real time monitoring of the distance between the
transducer and the rectal wall (in A mode) associated with the automatic readjustment of the position of the focal point allows for a positioning that is safe and precise.
Furthermore, the physician can choose the length of the lesion from 19 to 24 mm which ensures an adapted treatment.
For a perfect control of the lesion :
The use of the cavitation phenomenon (Ablatherm HIFU Induced Cavitation Technology) allows for a
better control of the geometry of the lesion that can be
as long as 24 mm. Due to the variable length of the
lesion, the AP diameter of the prostate can generally
be treated in one session using the same probe.
For an optimal time of treatment :
All the firing and control phases are automatic which optimizes the treatment of the entire gland
(1h30 for 30 cc).
Up to 81 Months Study, A. Gelet et al. : 145 patients with an inclusion PSA lower or equal to 30 ng/ml and up to 81 months follow-up after the Ablatherm treatment.
Results Up to 84 % follow-up with disease free progression at 5 years with combined biopsy and PSA criteria and actuarial survival curve with a plateau after 18 months for patients with PSA ≤ 10 and Gleason score ≤ 6.
PRESERVED QUALITY OF LIFE
Low Acute Morbidity
and No Chronic Toxicity
Confirmed by the study in Munich
The Ablatherm offers an actual treatment strategy for sexual function preservation, without oncologic compromise due to the unique possibility of retreatment.
Death (intra and post-op)
Rectal wall burn
Stress Incontinence Grade I (mean 27 days)
Stress Incontinence Grade II (mean 32 days)